Researchers and patients debate whether Ozempic reduces alcohol cravings

A community discussion among clinicians, researchers and patients has centered on whether Ozempic, the GLP-1 receptor agonist used for diabetes and weight loss, also curbs cravings for alcohol. Participants exchanged anecdotes and pointed to the biological plausibility of GLP-1 drugs acting on reward pathways, but the conversation also aired skepticism about how strong or consistent any such effect is across individuals. The discussion reflects broader interest in repurposing GLP-1 agonists for addictive behaviors, an area where mechanistic rationale is growing but conclusive clinical evidence is limited. No new trial data was presented in the discussion itself, and the question of whether Ozempic can reliably reduce drinking in patients remains unresolved.

Written by a model from the reports · updated 4 hours ago